NantKwest Appoints VP Of Research And Clinical Development
This article was originally published in Scrip
Executive Summary
NantKwest, an immunotherapy company focused on the immune system, has appointed Fatih M. Uckun vice president of research and clinical development. Prior to joining NantKwest, Uckun was president of Ares Pharmaceuticals and he was also a professor in the department of pediatrics at the Keck School of Medicine of the University of Southern California and head of translational research in leukemia and lymphoma of the Children’s Center for Cancer and Blood Diseases.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.